Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss...

Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to
Discuss 2009 First Quarter Results

Wednesday, May 6, 2009
9:00 a.m. EDT

1-800-814-4860

Webcast: http://www.nucryst.com/web_casts.htm

CALGARY, April 29 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp.
invites analysts and investors to participate in a briefing on Wednesday, May
6, 2009, with David B. Holtz, Interim President & Chief Executive Officer, and
Chief Financial Officer, regarding the Company's 2009 first quarter results.
The briefing, via conference call, is set for 9:00 a.m. EDT. To participate,
please call the toll-free number 1-800-814-4860. In addition to standard
disclosure over wire services, a news release with the first quarter results
will be posted on the NUCRYST web site prior to the call. To listen to the
call live on the Internet, please go to http://www.nucryst.com/web_casts.htm.
The briefing will be recorded and available for re-broadcast on demand for
seven days by dialing 1-877-289-8525. Callers will need to provide the
operator with the following reservation number: 21305201 followed by the
number sign. An audio file of the call will also be archived on the NUCRYST
web site.

About NUCRYST Pharmaceuticals

NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures
and commercializes medical products that fight infection and inflammation
using SILCRYST(TM), its patented atomically disordered nanocrystalline silver
technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care
coating products to Smith & Nephew plc, which markets these products in over
30 countries under their Acticoat(TM) trademark. NUCRYST has developed its
proprietary nanocrystalline silver in a powder form, referred to as NPI 32101,
for use in medical devices and as an active pharmaceutical ingredient.

Acticoat(TM) is a trademark of Smith & Nephew plc
SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.

SOURCE NUCRYST Pharmaceuticals Corp.

David Wills, Gillian McArdle, Investor Relations, NUCRYST Pharmaceuticals
Corp., (416) 504-8464, info@nucryst.com